Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus


Cite item

Full Text

Abstract

The review addresses the questions of the literature devoted to the problem of the influence of bariatric surgery on the course of diabetic nephropathy in patients with diabetes mellitus type 2 after achieving a surgically induced remission. This approach was shown to have positive aspects, such as decrease in creatinine, decrease in albuminuria, an increase in GFR, normalization of glycemia and blood pressure, "incretin effect"’s influence on the kidneys. Descriptions of the currently expected pathogenetic mechanisms involved in achieving the observed improvement in microvascular complications of diabetes, namely diabetic kidney disease, are also described in details.

About the authors

I I Larina

National Endocrinology Research Center, Ministry of Health of Russia

Email: irina.larina1993@mail.ru
н.с. отд-ния диабетической болезни почек и посттрансплантационной реабилитации Moscow, Russia

A S Severina

National Endocrinology Research Center, Ministry of Health of Russia

к.м.н., с.н.с. отд-ния диабетической болезни почек и посттрансплантационной реабилитации Moscow, Russia

M S Shamkhalova

National Endocrinology Research Center, Ministry of Health of Russia

д.м.н., зав. отд-нием диабетической болезни почек и посттрансплантационной реабилитации Moscow, Russia

M V Shestakova

National Endocrinology Research Center, Ministry of Health of Russia

академик РАН, д.м.н., проф., зам. директора НМИЦ эндокринологии по научной работе, директор Института диабета Moscow, Russia

References

  1. Hall M.E, do Carmo J.М, da Silva A.А, Juncos L.А, Wang Z, Hall J.E. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:75-88. doi: 10.2147/IJNRD.S39739
  2. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и др. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет. 2011;14(1):81-88. doi: 10.14341/2072-0351-6254
  3. Friedman A.N, Wolfe B. Is Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease? Clin J Am Soc Nephrol. 2016;11(3):528-535. doi: 10.2215/CJN.07670715
  4. Cohen R, Pechy F, Petry T, Correa J.L, Caravatto P.P, Tzanno-Martins C. Bariatric and metabolic surgery and microvascular complications of type 2 diabetes mellitus. J Bras Nefrol. 2015;37(3). doi: 10.5935/0101-2800.20150061
  5. Ritz E. Bariatric surgery and the kidney - much benefit, but also potential harm. Clin Kidney J. 2013;6(4):368-372. doi: 10.1093/ckj/sfs161
  6. Kambham N, Markowitz G.S, Valeri A.M, Lin J, D’Agati V.D. Obesity - related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498-1509.
  7. Li K, Zou J, Ye Z, et al. Effects of Bariatric Surgery on Renal Function in Obese Patients: A Systematic Review and Meta Analysis. Joles J.A, ed. PLoS One. 2016;11(10):e0163907. doi: 10.1371/journal.pone.0163907
  8. Галстян Г.Р., Шестакова Е.А., Скляник И.А. Ожирение и сахарный диабет 2 типа: поиск компромиссного терапевтического решения. Сахарный диабет. 2017;20(4):270-278. doi: 10.14341/DM8726
  9. Шестакова М.В., Скляник И.А., Дедов И.И. Возможна ли длительная ремиссия или излечение сахарного диабета 2-го типа в XXI веке? Терапевтический архив. 2017;89(10):4-11. doi: 10.17116/terarkh201789104-11
  10. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med. 2013;369(2):145-154. doi: 10.1056/NEJ Moa1212914
  11. Effect of a long - term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;2(10):801-809. doi: 10.1016/S2213-8587(14)70156-1
  12. Miras A.D, le Roux C.W. Mechanisms underlying weight loss after bariatric surgery. Nat Rev Gastroenterol Hepatol. 2013;10(10):575-584. doi: 10.1038/nrgastro.2013.119
  13. Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta - analysis. Am J Med. 2009;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041
  14. Schuster D.P, Teodorescu M, Mikami D, Foreman K, Rogers P, Needleman B.J. Effect of bariatric surgery on normal and abnormal renal function. Surg Obes Relat Dis. 2011;7(4):459-464. doi: 10.1016/j.soard.2010.11.015
  15. Standards of Medical Care in Diabetes - 2016 : Summary of Revisions. Diabetes Care. 2016;39(Suppl 1):S4-S5. doi: 10.2337/dc16-S003
  16. Standards of Medical Care in Diabetes - 2017: Summary of Revisions. Diabetes Care. 2017;40(Suppl 1):S4-S5. doi: 10.2337/dc17-S003
  17. Национальные клинические рекомендации по бариатрической и метаболической хирургии (проект). Ю.И. Яшков. Москва, 2014; 1-41 с.
  18. Fried M, Yumuk V, Oppert J.M, et al. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obes Surg. 2014;24(1):42-55. doi: 10.1007/s11695-013-1079-8
  19. Лечение морбидного ожирения у взрослых. Национальные клинические рекомендации. Ожирение и метаболизм. 2011;8(3):75-83. doi: 10.14341/2071-8713-4844
  20. Ершова Е.В., Трошина Е.А. Применение бариатрических операций при сахарном диабете 2 типа: в помощь практическому врачу. Ожирение и метаболизм. 2016;13(1):50-56. doi: 10.14341/omet2016150-56
  21. Курганов И.А., Матвеев Н.Л. Лапароскопическая бариатрическая хирургия как метод лечения сахарного диабета 2-го типа у пациентов с ожирением и метаболическим синдромом. Эндоскопическая хирургия. 2014;20(3):53-61.
  22. Дедов И.И., Яшков Ю.И., Ершова Е.В. Инкретины и их влияние на течение сахарного диабета 2 типа у пациентов с морбидным ожирением после бариатрических операций. Ожирение и метаболизм 2012;9(2):3-10. doi: 10.14341/omet201223-10
  23. O’Brien P, Mc Phail T, Chaston T, Dixon J. Systematic Review of Medium-Term Weight Loss after Bariatric Operations. Obes Surg. 2006;16(8):1032-1040. doi: 10.1381/096089206778026316
  24. Brethauer S.A, Hammel J.P, Schauer P.R. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis. 2009;5(4):469-475. doi: 10.1016/j.soard.2009.05.011
  25. Dixon J.B, O’Brien P.E, Playfair J, et al. Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes. JAMA. 2008;299(3). doi: 10.1001/jama.299.3.316
  26. Gill R.S, Birch D.W, Shi X, Sharma A.M, Karmali S. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6(6):707-713. doi: 10.1016/j.soard.2010.07.011
  27. Lee W-J, Ser K-H, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: Efficacy and change of insulin secretion. Surgery. 2010;147(5):664-669. doi: 10.1016/j.surg.2009.10.059
  28. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012 Apr 26;366(17):1577-1585. doi: 10.1056/NEJMoa1200111
  29. Schauer P.R, Bhatt D.L, Kirwan J.P, Wolski K, Brethauer S.A, Navaneethan S.D, Aminian A, Pothier C.E, Kim E.S, Nissen S.E, Kashyap S.R; STAMPEDE. Investigators N Engl J Med. 2014 May 22;370(21):2002-2013. doi: 10.1056/NEJMoa1401329
  30. Docherty N.G, le Roux C.W. Improvements in the metabolic milieu following Roux - en-Y gastric bypass and the arrest of diabetic kidney disease. Exp Physiol. 2014;99(9):1146-1153. doi: 10.1113/expphysiol.2014.078790
  31. Бордан Н.С., Яшков Ю.И. Эволюция билиопанкреатического шунтирования в лечении морбидного ожирения и сахарного диабета 2-го типа. Сахарный диабет. 2017;20(3):201-209. doi: 10.14341/7928
  32. Hou C-C, Shyu R-S, Lee W-J, Ser K-H, Lee Y-C, Chen S-C. Improved renal function 12 months after bariatric surgery. Surg Obes Relat Dis. 2013;9(2):202-206. doi: 10.1016/j.soard.2012.10.005
  33. Ковесди К.П., Фурс С., Зоккали К. и др. Ожирение и заболевания почек: скрытые последствия эпидемии. Нефрология и диализ. 2017;19(1):10-21. doi: 10.28996/1680-4422-2017-1-10-21
  34. Alexander J.W, Goodman H.R, Gersin K, Cardi M, Austin J, Goel S, Safdar S, Huang S, Woodle E.S. Gastric bypass inmorbidly obese patients with chronic renal failure and kidneytransplant. Transplantation. 2004 Aug 15;78(3):469-474.
  35. Alexander J.W, Goodman H. Gastric Bypass in Chronic Renal Failure and Renal Transplant. Nutr Clin Pract. 2007;22(1):16-21. doi: 10.1177/011542650702200116
  36. Neff K.J, Frankel A.H, Tam F.W.K, Sadlier D.M, Godson C, le Roux C.W. The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. Nephrol Dial Transplant. 2013;28(Suppl 4):iv73-iv82. doi: 10.1093/ndt/gft262
  37. Carlsson L.M.S, Romeo S, Jacobson P, et al. The incidence of albuminuria after bariatric surgery and usual care in swedish obese subjects (SOS): a prospective controlled intervention trial. Int J Obes. 2015;39(1):169-175. doi: 10.1038/ijo.2014.72
  38. Torgerson J, Sjöström L. The Swedish Obese Subjects (SOS) study - rationale and results. Int J Obes. 2001;25(S1):S2-S4. doi: 10.1038/sj.ijo.0801687
  39. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219-234. doi: 10.1111/joim.12012
  40. Sjöström L, Peltonen M, Jacobson P, et al. Association of Bariatric Surgery With Long - term Remission of Type 2 Diabetes and With Microvascular and Macrovascular Complications. JAMA. 2014;311(22):2297. doi: 10.1001/jama.2014.5988
  41. Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of Bilio-Pancreatic Diversion on Diabetic Complications: A 10-year follow - up. Diabetes Care. 2011;34(3):561-567. doi: 10.2337/dc10-1761
  42. Powers, P.S. Conservative treatments for morbid obesity. In: M. Deitel (ed.). Surgery for the morbidly obese patient. Philadelphia: Lea&Febiger; 1989. P.27-37.
  43. Hou C-C, Shyu R-S, Lee W-J, Ser K-H, Lee Y-C, Chen S-C. Improved renal function 12 months after bariatric surgery. Surg Obes Relat Dis. 2013;9(2):202-206. doi: 10.1016/j.soard.2012.10.005
  44. Fenske W.K, Dubb S, Bueter M, et al. Effect of bariatric surgery - induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013;9(4):559-568. doi: 10.1016/j.soard.2012.03.009
  45. Bueter M, Dubb S.S, Gill A, et al. Renal cytokines improve early after bariatric surgery. Br J Surg. 2010;97(12):1838-1844. doi: 10.1002/bjs.7264
  46. Brethauer S.A, Aminian A, Romero-Talamás H, et al. Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus. Ann Surg. 2013 Sep:1. doi: 10.1097/SLA.0b013e3182a5034b.
  47. Jose B, Ford S, Super P, Thomas G.N, Dasgupta I, Taheri S. The effect of biliopancreatic diversion surgery on renal function a retrospective study. Obes Surg. 2013 May;23(5):634-637. doi: 10.1007/s11695-012-0851-5
  48. Chang A.R, Chen Y, Still C, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int. 2016;90(1):164-171. doi: 10.1016/j.kint.2016.02.039
  49. Afsar B, Vaziri N.D, Aslan G, Tarim K, Kanbay M. Gut hormones and gut microbiota: implications for kidney function and hypertension. J Am Soc Hypertens. 2016;10(12):954-961. doi: 10.1016/j.jash.2016.10.007
  50. Яшков Ю.И., Ершова Е.В. «Метаболическая» хирургия. Ожирение и метаболизм. 2011;8(3):13-17. doi: 10.14341/2071-8713-4831
  51. Laferrere B, Heshka S, Wang K, et al. Incretin Levels and Effect Are Markedly Enhanced 1 Month After Roux - en -Y Gastric Bypass Surgery in Obese Patients With Type 2 Diabetes. Diabetes Care. 2007;30(7):1709-1716. doi: 10.2337/dc06-1549
  52. Lang F, Ottl I, Häussinger D, Deetjen P, Ahloulay M, Bankir L. Renal hemodynamic response to intravenous and oral amino acids in animals. Semin Nephrol. 1995 Sep;15(5):415-8.
  53. Moreno C, Mistry M, Roman R.J. Renal effects of glucagon - like peptide in rats. Eur J Pharmacol. 2002;434(3):163-167. doi: 10.1016/S0014-2999(01)01542-4
  54. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: A systematic review and meta - analysis. Surgery. 2007;142(4):621-635. doi: 10.1016/j.surg.2007.07.018
  55. Шестакова Е.А., Ильин А.В., Шестакова М.В., Дедов И.И. Глюкозозависимый инсулинотропный полипептид - новое звено в развитии ожирения. Ожирение и метаболизм. 2015;12(1):16-19. doi: 10.14341/OMET2015116-19
  56. Tanner R.M, Brown T.M, Muntner P. Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease. Curr Hypertens Rep. 2012;14(2):152-159. doi: 10.1007/s11906-012-0254-y
  57. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int. 2014;85(3):579-589. doi: 10.1038/ki.2013.427
  58. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon - like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141(1-3):120-128. doi: 10.1016/j.regpep.2006.12.016
  59. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med. 2002;8(7):738-742. doi: 10.1038/nm727
  60. Fulurija A, Lutz T.A, Sladko K, et al. Vaccination against GIP for the Treatment of Obesity. Bartolomucci A, ed. PLoS One. 2008;3(9):e3163. doi: 10.1371/journal.pone.0003163
  61. Ronn J, Jensen E.P, Wewer Albrechtsen N.J, Holst J.J, Sorensen C.M. Glucagon - like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors. Physiol Rep. 2017;5(23):e13503. doi: 10.14814/phy2.13503
  62. Kim M, Platt M.J, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567-575. doi: 10.1038/nm.3128
  63. Yu M, Moreno C, Hoagland K.M, Dahly A, Ditter K, Mistry M, Roman R.J. Antihypertensive effect of glucagon - like peptide 1 in Dahl salt - sensitive rats. J Hypertens. 2003 Jun;21(6):1125-1135. doi: 10.1097/01.hjh.0000059046.65882.49
  64. Gutzwiller J.P, Tschopp S, Bock A, Zehnder C.E, Huber A.R, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon - like peptide 1 induces natriuresis in healthy subjects and in insulin - resistant obese men. J Clin Endocrinol Metab. 2004 Jun;89(6):3055-3061. doi: 10.1210/jc.2003-031403
  65. Tonneijck L, Smits M.M, Muskiet M.H.A, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double - blind, placebo - controlled trial. Diabetologia. 2016;59(7):1412-1421. doi: 10.1007/s00125-016-3938-z
  66. Skov J, Pedersen M, Holst J.J, et al. Short - term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes Obes Metab. 2016;18(6):581-589. doi: 10.1111/dom.12651
  67. Von Scholten B.J, Persson F, Rosenlund S, et al. The effect of liraglutide on renal function: A randomized clinical trial. Diabetes Obes Metab. 2017;19(2):239-247. doi: 10.1111/dom.12808
  68. Thakar C.V, Kharat V, Blanck S, Leonard A.C. Acute kidney injury after gastric bypass surgery. Clin J Am Soc Nephrol. 2007 May;2(3):426-430.
  69. Петросян Э.К. Подоцит: строение и роль в развитии нефротического синдрома (Обзор литературы). Нефрология и диализ. 2006;8(2):112-121.
  70. Zhang Q, Davis K.J, Hoffmann D, Vaidya V.S, Brown R.P, Goering P.L. Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats. Biomark Med. 2014;8(1):85-94. doi: 10.2217/bmm.13.106
  71. Canales B.K, Reyes L, Reinhard M.K, Khan S.R, Goncalves C.G, Meguid M.M. Renal glomerular and tubular injury after gastric bypass in obese rats. Nutrition. 2012;28(1):76-80. doi: 10.1016/j.nut.2011.03.003
  72. Koukoulaki M, Spyropoulos C, Hondrogiannis P, et al. Neutrophil Gelatinase-Associated Lipocalin as a Biomarker of Acute Kidney Injury in Patients with Morbid Obesity Who Underwent Bariatric Surgery. Nephron Extra. 2013;3(1):101-105. doi: 10.1159/000354892
  73. Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, Jennings P. Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant. 2010;25(6):1896-1903. doi: 10.1093/ndt/gfp748
  74. De Silva P.M.C.S, Mohammed Abdul K.S, Eakanayake E.M.D.V, et al. Urinary Biomarkers KIM-1 and NGAL for Detection of Chronic Kidney Disease of Uncertain Etiology (CKDu) among Agricultural Communities in Sri Lanka. Vinetz J.M, ed. PLoS Negl Trop Dis. 2016;10(9):e0004979. doi: 10.1371/journal.pntd.0004979

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies